Biomedical Systems Launches Next Generation eCOA Technology
Biomedical Systems, a premier global provider of centralized diagnostic services, launches its second generation clinical outcome assessment software offering three easy-to-use platforms to collect patient data.
Biomedical Systems, a global provider of centralized diagnostic services, launched its second generation clinical outcome assessment software offering three platforms to collect patient data: the home, investigative site and the web. In addition, the Android smartphone is part of the home technology and the Android tablet is used at the site. Biomedical Systems provides eCOA technology along with cardiac safety, pulmonary function and imaging centralized diagnostic services.
The second version eCOA technology, updating the first which launched in January 2013, now includes the following features:
- More flexible software
- Improved compliance
- Improved ease of use for both sites and patients
- More reliable data transmission
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
